Business
Suda Pharmaceuticals share price soars 200% on TGA approval – Motley Fool Australia
The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.
The Suda Pharmaceuticals Ltd(ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administration). ZolpiMist is an oral spray for the treatment of insomnia.
In an investor presentation released by Suda Pharmaceuticals earlier this month, the company estimated the market for insomnia treatments will be approximately US$4 billion by 2026. Furthermore, a…
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News14 hours agoRates on hold; pressure builds for cuts in May